- Home
- SGN vs SONN Comparison
SGN vs SONN Comparison
Compare SGN & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- SONN
- Stock Information
- Founded
- SGN 2019
- SONN N/A
- Country
- SGN United States
- SONN United States
- Employees
- SGN N/A
- SONN N/A
- Industry
- SGN
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- SGN
- SONN Health Care
- Exchange
- SGN Nasdaq
- SONN Nasdaq
- Market Cap
- SGN 3.8M
- SONN 3.8M
- IPO Year
- SGN 2023
- SONN N/A
- Fundamental
- Price
- SGN $1.04
- SONN $4.15
- Analyst Decision
- SGN
- SONN Strong Buy
- Analyst Count
- SGN 0
- SONN 1
- Target Price
- SGN N/A
- SONN $20.00
- AVG Volume (30 Days)
- SGN 863.1K
- SONN 5.7M
- Earning Date
- SGN 08-18-2025
- SONN 08-13-2025
- Dividend Yield
- SGN N/A
- SONN N/A
- EPS Growth
- SGN N/A
- SONN N/A
- EPS
- SGN N/A
- SONN N/A
- Revenue
- SGN $529,282.00
- SONN $1,000,000.00
- Revenue This Year
- SGN N/A
- SONN $5,376.22
- Revenue Next Year
- SGN N/A
- SONN N/A
- P/E Ratio
- SGN N/A
- SONN N/A
- Revenue Growth
- SGN 8.42
- SONN 978.39
- 52 Week Low
- SGN $0.44
- SONN $1.08
- 52 Week High
- SGN $36.70
- SONN $10.02
- Technical
- Relative Strength Index (RSI)
- SGN 49.29
- SONN 93.49
- Support Level
- SGN $1.01
- SONN $1.10
- Resistance Level
- SGN $1.35
- SONN $1.17
- Average True Range (ATR)
- SGN 0.15
- SONN 0.29
- MACD
- SGN -0.02
- SONN 0.20
- Stochastic Oscillator
- SGN 27.40
- SONN 92.42
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.